CompletedPhase 2NCT05406479
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
Studying Leprosy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Tropical Medicine, Belgium
- Principal Investigator
- Younoussa AssoumaniDamien Foundation Comoros
- Intervention
- BE-PEP (Bedaquiline)(drug)
- Enrollment
- 313 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- Fondation Damien, Gege, Ndzuwani, Comoros
Collaborators
Damien Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05406479 on ClinicalTrials.govOther trials for Leprosy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06761469Leprosy Active Searching Trial in BrazilHospital Alemão Oswaldo Cruz
- RECRUITINGNANCT06819449Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy PatientsSouth Valley University
- RECRUITINGNCT06683690TGF β 1 Expression Related Gene PolymorphismAswan University
- RECRUITINGPHASE3NCT05597280Bedaquiline Enhanced Post ExpOsure Prophylaxis for LeprosyInstitute of Tropical Medicine, Belgium
- RECRUITINGPHASE2NCT05243654Efficacy and Tolerability of Adjunct Metformin for Multibacillary LeprosyOxford University Clinical Research Unit Indonesia
- RECRUITINGNANCT06222372Novel Interventions and Diagnostic Tests for LeprosyAnnemieke Geluk